PT - JOURNAL ARTICLE AU - Paul Brandily AU - Clément Brébion AU - Simon Briole AU - Laura Khoury TI - A Poorly Understood Disease? The Unequal Distribution of Excess Mortality Due to COVID-19 Across French Municipalities<sup>*</sup> AID - 10.1101/2020.07.09.20149955 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.09.20149955 4099 - http://medrxiv.org/content/early/2020/07/10/2020.07.09.20149955.short 4100 - http://medrxiv.org/content/early/2020/07/10/2020.07.09.20149955.full AB - While COVID-19 was already responsible for more than 500,000 deaths worldwide as of July 3, 2020, very little is known on the socio-economic heterogeneity of its impact on mortality. In this paper, we combine several administrative data sources to estimate the relationship between mortality due to COVID-19 and poverty at a very local level (i.e. the municipality level) in France, one of the most severely hit country in the world. We find strong evidence of an income gradient in the impact of the pandemic on mortality: it is twice as large in the poorest municipalities compared to other municipalities. We then show that both poor housing conditions and higher occupational exposure are likely mechanisms. Overall, these mechanisms accounts for up to 60% of the difference observed between rich and poor municipalities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work has been produced through statistical analysis of non-individual (municipality level) and publicly available data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMost data used in this paper is publicly available. The rest of the data is available for research purpose under agreement with the CASD.